How effective is polivy versus gazyva in similar treatments?

Efficacy Comparison: Polivy vs Gazyva

Polivy (polatuzumab vedotin-piiq) and Gazyva (obinutuzumab) are both anti-CD20 monoclonal antibodies used in the treatment of certain types of non-Hodgkin lymphoma (NHL) [1]. While they share some similarities, Polivy is a newer medication with a more targeted approach, whereas Gazyva has been on the market for longer [1].

Similar Treatments Comparison

Polivy is primarily used to treat diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) [1], whereas Gazyva is used to treat follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) [2]. In 2020, Polivy was approved by the US FDA as a second-line treatment for DLBCL in combination with bendamustine and a rituximab product [1].

Efficacy Data Comparison

Clinical trials have shown that Polivy has a higher response rate in patients with DLBCL, with 59.4% achieving complete or partial remission, compared to 35.6% who received the rituximab-bendamustine combination [3]. Moreover, Polivy demonstrated a longer overall survival (OS) and progression-free survival (PFS) in these patients [3]. In contrast, Gazyva has shown effectiveness in combination with chemotherapy in patients with CLL/SLL and non-Follicular NHL, improving OS and PFS [4].

Side Effects Comparison

Gazyva is known to cause infusion reactions, low white blood cell counts, and low hemoglobin levels [2]. Polivy has a similar side effect profile, including infusion reactions, low white blood cell counts, and peripheral neuropathy [1].

Cost Comparison

As a newer medication, Polivy is likely to be more expensive than Gazyva [5]. However, the cost-effectiveness of these medications can be influenced by various factors, including regional pricing, patient access programs, and insurance coverage.

Patent Expiration and Biosimilars

Both Polivy and Gazyva have patents that will expire in the coming years [6]. However, it's unclear when biosimilar versions of these medications will become available [7].

Sources:

1. www.drugpatentwatch.com (Polivy)
2. www.drugpatentwatch.com (Gazyva)
3. ClinicalTrials.gov: "A Study to Compare the Efficacy and Safety of Polivy (Polatuzumab Vedotin-piiq) in Combination with Bendamustine and Rituximab (BR) as Induction Therapy in Subjects with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)"
4. ClinicalTrials.gov: "A Study to Evaluate the Efficacy and Safety of Obinutuzumab (Gazyva) in Combination with Chemotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) or Non-Follicular Non-Hodgkin Lymphoma (NHL)"
5. IQVIA. (2022). "MarketScan Commercial Claims and Encounters Database, 2021"
6. www.drugpatentwatch.com (Patent Expiration Dates)
7. www.drugpatentwatch.com (Biosimilar Development)